The US FDA is promising to take a flexible, transparent approach to the development and implementation of new pediatric study requirements for certain cancer drugs under the FDA Reauthorization Act (FDARA).
The agency intends use a transparent process to generate a list of molecular targets potentially relevant to pediatric cancers and...







